adidas' prototype shoe made from spider silk, @ Amsilk

Running made by biotech

Adidas has presented the world’s first lightweight racing shoe made by recombinantly produced silk fibers. 

Read more
Jakob Dynnes Hansen, © Acesion Pharma

Acesion Pharma: New head of finance

Danish biotech Acesion Pharma has hired Jakob Dynnes Hansen as its Chief Financial Officer. He joins from Evolva, a Swiss biotech company, where he has been CFO since 2007.
Read more
Pascal Besman, © PharmaMar

PharmaMar: Pushing the borders

PharmaMar is driving the expansion of its US operations. To this end, the company has appointed Pascal Besman to the newly created role of Chief Operation Officer of the marine-derived oncology drug developers US subsidiary, PharmaMar US. 
Read more
Brenda Reynolds, ©iQur

BIA: Three new faces on the board

The BIA has added three new members to the Board of Directors. Calchan CEO Brenda Reynolds (pictured), Immunocore Chief Business Officer Eva-Lotta Allan and Polar Capital’s Partner – Healthcare Dan Mahony will join the board of the British BioIndustry Association from January 2017.
Read more
Researcher at Martinsried-headquarters of Medigene, © Medigene

Medigene offers neoantigen-specific TCRs

Until mid-October, cancer immunotherapy play Medigene AG was a pure drug developer. With a potential US$1bn TCR-contract manufacturing deal with Bluebird Bio, it widened its business focus. Now, the company presented a process that delivers neospecific anti-tumour TCRs.

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more
Mortality and population size of inflamed and non-inflamed tumour subtypes, x-axis: relative tumour mutation frequency (from low [left] to high [right]; © Roche; PAnC: Pancreatic cancer, AML: Acute myelogenous leukaemia; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; GBM: Glioblastoma multiforme; CRC: colorectal carcinoma; OvCa: Ovarial carcinoma; SCCHN: Squamous cell carcinoma of head and neck; TNBC: Triple-negative breast cancer; NHL: Non-Hodgkin lymphoma; GC: Gastric cancer, UBC: Urothelial bladder cancer; NSCLC: Non-small cell lung cancer

Roche ramps up immunotherapy R&D

Swiss cancer meds world market leader Roche intensifies its focus on translational research to broaden the scope of cancer immunotherapies. 

Read more